Management and Outcomes for Neovascular Age-Related Macular Degeneration

Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis

“…Although we did not conduct a sensitivity analysis, potential misclassification of nAMD may have occurred. However, this definition is consistent with those used in prior real-world studies, 17,45 and the distribution of nAMD-related outpatient visits over follow up from our study suggest this definition is specific. This study identified incident patients as a subset of the prevalent cohort.…”

“…16 Anti-VEGF therapy for nAMD places a burden on patients and health care system, as it requires multiple treatments that entail frequent office visits and ancillary testing. However, the frequency of anti-VEGF therapy over the first year in US clinical practice appears to be lower than the more frequent schedules used in randomized clinical trials [16][17][18][19] with discontinuation rates as high as 57% in the first year. 19 This suggests potential undertreatment in patients with nAMD exists.…”

“…33 First-year anti-VEGF injection frequency in the incident cohort is similar to previous estimates of real-world anti-VEGF treatment patterns among treatment-naive patients with nAMD (mean of 5.6-6.0 injections in the first year). 16,17 These realworld estimates are low when compared with randomized clinical trials that suggest at least 7-8 anti-VEGF injections are needed during the first year to gain meaningful change in visual acuity. [34][35][36] A lower than optimal number of anti-VEGF injections may lead to worse clinical outcomes and higher downstream costs.…”

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

“…32 Experience has shown that biosimilars in other fields of medicine can contribute to reducing healthcare costs and improve patient's access to therapies with approved labels. 10-13 33 34 Future research is warranted to investigate the contribution of RBZ biosimilars to reducing undertreatment in nAMD [35][36][37][38][39] and improving the visual outcomes in the clinical practice setting.…”

The Short-Term Compliance and Concordance to in Clinic Testing for Tablet-Based Home Monitoring in Age-Related Macular Degeneration

“…However, despite knowing the importance of early detection and the commencement of treatment, in many instances, patients are still presenting with significant loss of central vision before treatment is initiated. 7,8 Standard care for individuals at high risk of progression to late-stage AMD is routine clinical reviews (typically 6 monthly) and home monitoring with the Amsler grid. This method, used since 1945, 9 increases the likelihood of detecting early visual changes, such as metamorphopsia, suggestive of progression to neovascular complications.…”